Middle East and Africa Menopausal Disorder Treatment Market – Industry Trends and Forecast to 2027

  • Pharmaceutical
  • Published Report
  • Oct 2020
  • MEA
  • 350 Pages
  • No of Tables: 242
  • No of Figures: 48

Middle East and Africa Menopausal Disorder Treatment Market, By Stages (Menopause, Postmenopause and Perimenopause), Type (Hormonal Therapy and Non-Hormonal Therapy), Menopause Symptoms (Vasomotor Symptoms, Atrophic Vaginitis, Osteoporosis, Joint Pain, Weight Gain, Dyspareunia, Depression and Others), Dosage Form (Tablets, Creams, Gels, Rings/Insert, Patch/Films, Injection Shot, Spray and Others), Route of Administration (Oral, Vaginal, Transdermal and Parenteral), End User (Hospital, Clinics and Home Healthcare), Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy), Country (Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and Rest of Middle East and Africa) Industry Trends and Forecast to 2027

Middle East and Africa Menopausal Disorder Treatment MarketMarket Analysis and Insights : Middle East and Africa Menopausal Disorder Treatment Market

Middle East and Africa menopausal disorder treatment market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 5.3% in the forecast period of 2020 to 2027 and is expected to reach USD 533.43 million by 2027.

Growing cases of hormone related disorders and presence of favorable reimbursement are the major drivers which propelled the demand of the market in the forecast period.

Menopausal disorder treatment comprises features such presence of novel pipeline drugs will impact in launching new product by the manufactures into the market which enhance its demand as well as high demand of disease specific treatment leads the demand of accurate menopausal disorder treatment.

Currently various research studies are taking place which is expected to create a competitive advantage for manufacturers to develop new and innovative menopausal disorder treatment which is expected to provide various other opportunities in the menopausal disorder treatment market. However, inadequate knowledge about menopause in some developing countries and patent expiry expected to restraint the market growth in the forecast period.

The menopausal disorder treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.

Middle East and Africa Menopausal Disorder Treatment MarketMiddle East and Africa Menopausal Disorder Treatment Market Scope and Market Size

Menopausal disorder treatment market is segmented into seven notable segments which are based on the basis of stages, type, dosage form, menopause symptoms, route of administration, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of stages, the Middle East and Africa menopausal disorder treatment market is segmented into menopause, postmenopause and perimenopause. In 2020, menopause segment is dominating the market due to increasing cases of cancers among women which led them to go through hysterectomy, radiation therapy and chemotherapy which makes ovaries nonfunctional and hence lack of estrogen enhances the chances of menopause.
  • On the basis of type, the Middle East and Africa menopausal disorder treatment market is segmented into hormonal therapy and non-hormonal therapy. In 2020, hormonal therapy segment is dominating in the market as it is most commonly used for getting relieve from vaginal dryness and hot flushes and reduces the risk of bone breakage.
  • On the basis of menopause symptoms, the Middle East and Africa menopausal disorder treatment market is segmented into vasomotor symptoms, atrophic vaginitis, osteoporosis, joint pain, weight gain, dyspareunia, depression and others. In 2020, vasomotor symptoms is expected to dominate the market as it is the primary symptom associated with menopause and maximum number of market players are conducting clinical trials with an aim to provide innovative medicine for menopause disorder treatment.
  • On the basis of dosage form, the Middle East and Africa menopausal disorder treatment market is segmented into tablets, creams, gels, rings/insert, patch/films, injection shot, spray and others. In 2020, tablets segment is dominating the market as it is easy to modify drug dosage with tablets, moreover tablets have high bioavailability.
  • On the basis of route of administration, the Middle East and Africa menopausal disorder treatment market is segmented into oral, vaginal, transdermal and parenteral. Parenteral segment is further segmented into intravenous and subcutaneous. In 2020, oral segment is dominating the market as it is removes the fear of needle sticks and allows patients self - compliance.
  • On the basis of end user, the Middle East and Africa menopausal disorder treatment market is segmented into hospital, clinics and home healthcare. In 2020, hospitals segment is dominating the market as hospitals have advanced healthcare infrastructure along with trained professionals.
  • On the basis of distribution channel, the Middle East and Africa menopausal disorder treatment market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. In 2020, hospital pharmacy segment is dominating the market because hospital pharmacies provide patients with variety of medicines used for treatment of menopausal disorder symptoms.

Menopausal Disorder Treatment Market Country Level Analysis

The menopausal disorder treatment market is analyzed and market size information is provided the basis of stages, type, menopause symptoms, dosage form, route of administration, end-user and distribution channel.

The countries covered in the Menopausal disorder treatment market report are the Saudi Arabia, South Africa, U.A.E., Israel, Kuwait, Egypt and Rest of Middle East and Africa.

Menopause segment in Middle East and Africa region is expected to grow with the highest growth rate in the forecast period of 2020 to 2027 due to rapidly growing manufacturing sites. Saudi Arabia is leading the growth of the Middle East and Africa market and menopause segment is dominating in this country due to rise in prevalence of hormonal & reproductive disorders in among female.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Rising Awareness about the Treatment and Vulnerable Aging Population of Menopause Women are boosting the Market Growth of Menopausal Disorder Treatment

Menopausal disorder treatment market also provides you with detailed market analysis for every country growth in menopausal disorder treatment industry with menopausal disorder treatment drugs sales, impact of advancement in the menopausal disorder treatment technology and changes in regulatory scenarios with their support for the menopausal disorder treatment market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Menopausal Disorder Treatment Market Share Analysis

Menopausal disorder treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Menopausal disorder treatment market.

The major companies which are dealing in the menopausal disorder treatment are Allergan (a subsidiary of AbbVie, Inc.), GlaxoSmithKline plc, Dr. Reddy’s Laboratories Ltd., Pfizer Inc., Mylan N.V., Abbott, Besins Healthcare, Mithra Pharmaceuticals, Novartis AG, Novo Nordisk A/S, among others.

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the menopausal disorder treatment market.

For instance,

  • In May 2020, AbbVie Inc. completed the acquisition of Allergan, which is focused on development of products for different medical purposes. Allergan is also focused on development and manufacturing of products used for menopausal disorder treatment. This acquisition strengthened the company’s product portfolio used for menopausal disorder treatment.
  • In November 2019, Knight Therapeutics Inc. and TherapeuticsMD, Inc. had submitted a new drug application to Health Canada for BIJUVA and received acceptance as well. This initiative paved the way for the company to commercialize its product in Canada, which allow it to generate more revenue.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the menopausal disorder treatment market which also provides the benefit for organization to improve their offering for menopausal disorder treatment.

Customization Available: Middle East and Africa Menopausal Disorder Treatment Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.


SKU-

LIST OF TABLES

TABLE 1 MIDDLE EAST AND AFRICA MENOPAUSAL DISORDER TREATMENT MARKET, PIPELINE ANALYSIS

TABLE 2 MEDICINES SUBJECTED TO PATENT EXPIRY

TABLE 3 MIDDLE EAST AND AFRICA MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES 2019-2027 (USD MILLION)

TABLE 4 MIDDLE EAST AND AFRICA MENOPAUSE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 5 MIDDLE EAST AND AFRICA POSTMENOPAUSE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 6 MIDDLE EAST AND AFRICA PERIMENOPAUSE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 7 MIDDLE EAST AND AFRICA MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2019-2027 (USD MILLION)

TABLE 8 MIDDLE EAST AND AFRICA HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 9 MIDDLE EAST AND AFRICA HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 10 MIDDLE EAST AND AFRICA HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 11 MIDDLE EAST AND AFRICA 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 12 MIDDLE EAST AND AFRICA CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 13 MIDDLE EAST AND AFRICA ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 14 MIDDLE EAST AND AFRICA ESTRADIOL ACETATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 15 MIDDLE EAST AND AFRICA HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 16 MIDDLE EAST AND AFRICA 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 17 MIDDLE EAST AND AFRICA ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 18 MIDDLE EAST AND AFRICA CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 19 MIDDLE EAST AND AFRICA HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 20 MIDDLE EAST AND AFRICA MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 21 MIDDLE EAST AND AFRICA NON HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 22 MIDDLE EAST AND AFRICA NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 23 MIDDLE EAST AND AFRICA NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 24 MIDDLE EAST AND AFRICA ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 25 MIDDLE EAST AND AFRICA NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 26 MIDDLE EAST AND AFRICA HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS 2019-2027 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA VASOMOTOR SYMPTOMS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 29 MIDDLE EAST AND AFRICA ATROPHIC VAGINITIS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 30 MIDDLE EAST AND AFRICA OSTEOPOROSIS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 31 MIDDLE EAST AND AFRICA JOINT PAIN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 32 MIDDLE EAST AND AFRICA WEIGHT GAIN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 33 MIDDLE EAST AND AFRICA DYSPAREUNIA IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA DEPRRESSION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 35 MIDDLE EAST AND AFRICA OTHERS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 36 MIDDLE EAST AND AFRICA MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM 2019-2027 (USD MILLION)

TABLE 37 MIDDLE EAST AND AFRICA TABLETS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 38 MIDDLE EAST AND AFRICA CREAMS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 39 MIDDLE EAST AND AFRICA GELS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 40 MIDDLE EAST AND AFRICA RINGS/INSERTS/INSERTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 41 MIDDLE EAST AND AFRICA PATCH/FILMS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 42 MIDDLE EAST AND AFRICA INJECTION SHOT IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 43 MIDDLE EAST AND AFRICA SPRAY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 44 MIDDLE EAST AND AFRICA OTHERS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 45 MIDDLE EAST AND AFRICA MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)

TABLE 46 MIDDLE EAST AND AFRICA ORAL IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 47 MIDDLE EAST AND AFRICA VAGINAL IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 48 MIDDLE EAST AND AFRICA TRANSDERMAL IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 49 MIDDLE EAST AND AFRICA PARENTERAL IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 50 MIDDLE EAST AND AFRICA PARENTERAL IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 51 MIDDLE EAST AND AFRICA MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER 2019-2027 (USD MILLION)

TABLE 52 MIDDLE EAST AND AFRICA HOSPITAL IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 53 MIDDLE EAST AND AFRICA CLINICS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 54 MIDDLE EAST AND AFRICA HOME HEALTHCARE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 55 MIDDLE EAST AND AFRICA MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBITION CHANNEL, 2019-2027 (USD MILLION)

TABLE 56 MIDDLE EAST AND AFRICA HOSPITAL PHARMACY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 57 MIDDLE EAST AND AFRICA RETAIL PHARMACY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 58 MIDDLE EAST AND AFRICA ONLINE PHARMACY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 59 MIDDLE EAST & AFRICA MENOPAUSAL DISORDER TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 60 MIDDLE EAST & AFRICA MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)

TABLE 61 MIDDLE EAST & AFRICA MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 62 MIDDLE EAST & AFRICA HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 63 MIDDLE EAST & AFRICA HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 64 MIDDLE EAST & AFRICA 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 65 MIDDLE EAST & AFRICA CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 66 MIDDLE EAST & AFRICA ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 67 MIDDLE EAST & AFRICA ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 68 MIDDLE EAST & AFRICA ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 69 MIDDLE EAST & AFRICA HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 70 MIDDLE EAST & AFRICA 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 71 MIDDLE EAST & AFRICA ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 72 MIDDLE EAST & AFRICA CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 73 MIDDLE EAST & AFRICA HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 74 MIDDLE EAST & AFRICA MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 75 MIDDLE EAST & AFRICA NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 76 MIDDLE EAST & AFRICA NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 77 MIDDLE EAST & AFRICA ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 78 MIDDLE EAST & AFRICA NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 79 MIDDLE EAST & AFRICA HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 80 MIDDLE EAST & AFRICA MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS,  2018-2027 (USD MILLION)

TABLE 81 MIDDLE EAST & AFRICA MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)

TABLE 82 MIDDLE EAST & AFRICA MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 83 MIDDLE EAST & AFRICA PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 84 MIDDLE EAST & AFRICA MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 85 MIDDLE EAST & AFRICA MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 86 SAUDI ARABIA MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)

TABLE 87 SAUDI ARABIA MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 88 SAUDI ARABIA HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 89 SAUDI ARABIA HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 90 SAUDI ARABIA 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 91 SAUDI ARABIA CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 92 SAUDI ARABIA ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 93 SAUDI ARABIA ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 94 SAUDI ARABIA ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 95 SAUDI ARABIA HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 96 SAUDI ARABIA 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 97 SAUDI ARABIA ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 98 SAUDI ARABIA CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 99 SAUDI ARABIA HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 100 SAUDI ARABIA MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 101 SAUDI ARABIA NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 102 SAUDI ARABIA NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 103 SAUDI ARABIA ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 104 SAUDI ARABIA NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 105 SAUDI ARABIA HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 106 SAUDI ARABIA MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS,  2018-2027 (USD MILLION)

TABLE 107 SAUDI ARABIA MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)

TABLE 108 SAUDI ARABIA MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 109 SAUDI ARABIA PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 110 SAUDI ARABIA MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 111 SAUDI ARABIA MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 112 SOUTH AFRICA MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)

TABLE 113 SOUTH AFRICA MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 114 SOUTH AFRICA HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 115 SOUTH AFRICA HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 116 SOUTH AFRICA 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 117 SOUTH AFRICA CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 118 SOUTH AFRICA ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 119 SOUTH AFRICA ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 120 SOUTH AFRICA ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 121 SOUTH AFRICA HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 122 SOUTH AFRICA 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 123 SOUTH AFRICA ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 124 SOUTH AFRICA CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 125 SOUTH AFRICA HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 126 SOUTH AFRICA MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 127 SOUTH AFRICA NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 128 SOUTH AFRICA NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 129 SOUTH AFRICA ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 130 SOUTH AFRICA NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 131 SOUTH AFRICA HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 132 SOUTH AFRICA MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS,  2018-2027 (USD MILLION)

TABLE 133 SOUTH AFRICA MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)

TABLE 134 SOUTH AFRICA MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 135 SOUTH AFRICA PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 136 SOUTH AFRICA MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 137 SOUTH AFRICA MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 138 UAE MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)

TABLE 139 UAE MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 140 UAE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 141 UAE HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 142 UAE 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 143 UAE CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 144 UAE ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 145 UAE ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 146 UAE ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 147 UAE HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 148 UAE 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 149 UAE ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 150 UAE CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 151 UAE HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 152 UAE MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 153 UAE NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 154 UAE NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 155 UAE ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 156 UAE NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 157 UAE HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 158 UAE MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS,  2018-2027 (USD MILLION)

TABLE 159 UAE MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)

TABLE 160 UAE MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 161 UAE PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 162 UAE MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 163 UAE MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 164 ISRAEL MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)

TABLE 165 ISRAEL MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 166 ISRAEL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 167 ISRAEL HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 168 ISRAEL 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 169 ISRAEL CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 170 ISRAEL ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 171 ISRAEL ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 172 ISRAEL ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 173 ISRAEL HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 174 ISRAEL 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 175 ISRAEL ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 176 ISRAEL CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 177 ISRAEL HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 178 ISRAEL MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 179 ISRAEL NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 180 ISRAEL NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 181 ISRAEL ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 182 ISRAEL NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 183 ISRAEL HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 184 ISRAEL MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS,  2018-2027 (USD MILLION)

TABLE 185 ISRAEL MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)

TABLE 186 ISRAEL MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 187 ISRAEL PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 188 ISRAEL MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 189 ISRAEL MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 190 KUWAIT MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)

TABLE 191 KUWAIT MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 192 KUWAIT HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 193 KUWAIT HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 194 KUWAIT 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 195 KUWAIT CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 196 KUWAIT ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 197 KUWAIT ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 198 KUWAIT ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 199 KUWAIT HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 200 KUWAIT 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 201 KUWAIT ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 202 KUWAIT CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 203 KUWAIT HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 204 KUWAIT MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 205 KUWAIT NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 206 KUWAIT NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 207 KUWAIT ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 208 KUWAIT NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 209 KUWAIT HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 210 KUWAIT MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS,  2018-2027 (USD MILLION)

TABLE 211 KUWAIT MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)

TABLE 212 KUWAIT MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 213 KUWAIT PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 214 KUWAIT MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 215 KUWAIT MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 216 NETHERLANDS MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)

TABLE 217 NETHERLANDS MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 218 NETHERLANDS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 219 NETHERLANDS HORMONAL THERAPY BY ESTROGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 220 NETHERLANDS 17Β-ESTRADIOL HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 221 NETHERLANDS CONJUGATED ESTROGENS HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 222 NETHERLANDS ESTRADIOL HEMIHYDARTE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 223 NETHERLANDS ESTRADIOL ACETATEHORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 224 NETHERLANDS ESTROPIPATE HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 225 NETHERLANDS HORMONAL THERAPY BY COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 226 NETHERLANDS 17Β-ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 227 NETHERLANDS ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 228 NETHERLANDS CONJUGATED ESTROGENS (E) + MEDROXYPROGESTRONE ACETATE (P) IN COMBINED ESTROGENS & PROGESTOGEN DRUGS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 229 NETHERLANDS HORMONAL THERAPY BY PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 230 NETHERLANDS MEDROXYPROGESTERONE ACETATE IN PROGESTOGEN IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 231 NETHERLANDS NON- HORMONAL THERAPY IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 232 NETHERLANDS NON-HORMONAL THERAPY BY MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 233 NETHERLANDS ANTI-DEPRESSANTS MEDICATION IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 234 NETHERLANDS NON-HORMONAL THERAPY BY SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 235 NETHERLANDS HERBAL SUPPLEMENTS IN MENOPAUSAL DISORDER TREATMENT MARKET, BY TYPE, 2018-2027 (USD MILLION)

TABLE 236 NETHERLANDS MENOPAUSAL DISORDER TREATMENT MARKET, BY MENOPAUSE SYMPTOMS,  2018-2027 (USD MILLION)

TABLE 237 NETHERLANDS MENOPAUSAL DISORDER TREATMENT MARKET, BY DOSAGE FORM, 2018-2027 (USD MILLION)

TABLE 238 NETHERLANDS MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 239 NETHERLANDS PARENTERAL ROUTE IN MENOPAUSAL DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 240 NETHERLANDS MENOPAUSAL DISORDER TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 241 NETHERLANDS MENOPAUSAL DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 242 REST OF MIDDLE EAST & AFRICA MENOPAUSAL DISORDER TREATMENT MARKET, BY STAGES, 2018-2027 (USD MILLION)

 

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions